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Stopped-flow spectroscopy is a powerful method for measuring very fast biological and chemical 
reactions. The technique however is often limited by the volumes of reactants needed to load the 
system. Here we present a simple adaptation of commercial stopped-flow system that reduces the 
volume needed by a factor of 4 to ≈120 µL.  After evaluation the volume requirements of the system 
we show that many standard myosin based assays can be performed using <100 µg of myosin.  This 
adaptation both reduces the volume and therefore mass of protein required and also produces data  
of similar quality to that produced using the standard set up.  The 100 µg of myosin required for 
these assays is less than that which can be isolated from 100 mg of muscle tissue.  With this reduced 
quantity of myosin, assays using biopsy samples become possible.  This will allow assays to be used 
to assist diagnoses, to examine the effects of post translational modifications on muscle proteins 
and to test potential therapeutic drugs using patient derived samples. 
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Highlights: 
• Reduced the volume of sample required in stopped-flow systems by a factor of 4 
• Many assays using muscle proteins can be completed with <100 µg of protein 
• This is the quantity of protein available from <100 mg of muscle tissues 
















Stopped-flow spectrophotometry is a powerful method for studying chemical and biochemical 
reactions on msec time scales [1] but often requires relatively large amounts of material.  This can be 
a serious limitation when studying expensive and/or difficult to make samples.  There are two major 
limitations to the sample requirements; the concentration of sample required to give the required 
signal sensitivity, and the volume of sample required by the equipment.  Major advances in 
sensitivity over recent years have enabled the concentrations of proteins being used to be reduced 
to sub micromolar, even for a weak signal such as intrinsic tryptophan fluorescence. This allows a 
greater efficiency of sample usage compared to a few years ago. 
In contrast, there has been relatively little change in the volume of sample needed.  Typically each 
shot of the stopped-flow uses at total of 20 μl for a 5 µl observation cell (or 100 µl for a 20 μl 
observations cell).  In a standard single mixing system this volume comes 50:50 from two syringes 
containing each reactant.  Of the order of five shots are normally collected to ensure reproducibility 
and to allow averaging of the signal to improve the ratio of signal to noise. Thus 50 or 250 µl of each 
sample are used per data point.  However, because of the way the systems are constructed there is a 
requirement to load between 0.5 to 1 ml of solution in each syringe to prime the system.  This is not 
a problem as a typical experiment can use one filling to complete several measurements.  E.g. using 
a fixed protein concentration mixed with a range of ligand concentrations, or repeating a single 
measurement at different temperatures.  Thus many measurements can be made from a single 
loading.  Other experimental protocols require a new filling for each measurement in which case the 
total volume required can be excessive for valuable proteins or proteins in limited supply. 
We have modified a standard commercial stopped-flow system to include sample loading loops just 
before the observation chamber.  This now allows data to be collected using a single loading of 120 
µl of each sample with no loss of sensitivity.  This represents a 4-8 fold reduction in the volume of 















measurement of the affinity of actin for myosin using ≈1 µg of the 42 kDa protein, actin (5 x 120 µL 
of a 30 nM sample). 
Here we describe the modification which, in principle, can be made to most commercial stopped-
flow systems, and demonstrate its utility for a variety of reactions using the muscle proteins actin, 
myosin, tropomyosin and the troponin complex (TnT, TnC and TnI).  The quantities of protein 
required are those which would be available for myosin isolated from a 100 mg human biopsy 
sample opening up a range of possible diagnostic applications. 
 
Methods: 
Design of the micro-volume system. 
The modification of the stopped-flow system is similar to that we reported previously to allow much 
wider range of temperature control of the stopped-flow [2].  A small module was constructed from 
PEEK containing flow lines, two 3-way valves and a set of 3 PTFE compression fittings (on the front 
and rear face) to match those on the face of the stopped-flow drive unit and the mixing/observation 
unit.  The unit was inserted between the stopped-flow drive unit and the mixing/observation 
chamber as illustrated in Fig 1.  The system flow circuit is illustrated in Fig 1A, while Fig 1B & 1C are 
photographs of the stopped-flow drive unit and micro-volume unit.  The micro-volume module 
design allowed approximately 120 µl of sample to be drawn into the loading loops leading to the 
mixing/observation chamber. Buffer from the standard drive syringes was then used to drive the 
sample from the loading loops through the mixing unit into the observation chamber.  Since the 
overall configuration of the system has not changed the overall performance of the equipment in 
terms of dead-time (the age of the sample on arrival in the observation chamber), and optical 















In a typical experiment 150 µl was pipetted into the conical loading cup avoiding air bubbles.  With 
the valve in the position to connect the loading cup to the observation cell, the stop syringe was 
used to draw 120 µl of sample into the loading line, and the valve was then switched to connect the 
drive syringe through loading loop to the observation cell.  The procedure could be repeated for the 
second sample loop if required. Using a 5 µl observation cell a series of 20 µl shots (10 µl from each 
drive syringe) were collected. Continuing to drive multiple shots will rinse the loading loops and cell 
and leave system primed with buffer ready for the next sample loading. 
Proteins 
Myosin subfragment 1 (S1) was obtained by extracting myosin from Rabbit psoas muscle [3] and 
digested with α-chymotrypsin [4]. A Sepharose FF column was used to purify the S1 which was 
freeze-dried in a 5 mM potassium phosphate buffer with 1% sucrose and stored at -80 °C. S1 powder 
was dissolved in experimental buffer and dialysed overnight to remove the sucrose and phosphate. 
The protein concentration was determined by absorbance at 280 nm (ε
1%
 = 7.9 cm
-1
, MW = 115 kDa) 
using a Varian Cary 50 Bio UV spectrophotometer. 
Actin was prepared from rabbit skeletal muscle [5]. Actin was labelled at cysteine-374 with pyrene 
for use in stopped-flow experiments with an average label content of ≈90% determined by protein 
and pyrene absorbance previously described [6]. 
Tropomyosin and troponin was purified during the actin purification using methods previously 
described [7,8].  
Myofibrils were prepared as previously described [9,10] with some modifications. Briefly mouse 
Gastrocnemius muscle strips equilibrated in fiber preparation buffer containing: 6 mM Imidazole, 8 
mM Mg-Acetate, 70 mM Propionate pH 7.0, 5 mM EGTA, 7 mM ATP, 1 mM NaN3. The buffer was 
exchanged twice before being left to permeabilize for 2 hours in fiber preparation buffer containing 















and kept at -20 °C until needed. To obtain myofibrils 60-100 mg of fibers were homogenised using an 
electric homogeniser (Dremel cordless moto-tool model 850) for 15 seconds at low speed (15,000 
rpm) and left to cool on ice for >1 minute. This was repeated 3-4 times. Myofibril integrity was 
checked using a light microscope, if large bundles of myofibrils were present then further 
homogenisation was performed to help break them up to individual myofibrils. Fibers were 
homogenised in a rigor-buffer containing: 50 mM Imidazole, 12 mM Mg-Acetate, 2 mM EGTA, and 
106 mM NaCl pH 7.0. Myofibril stopped-flow assays were conducted with 2’/3’-O-(N-Methyl-
anthranoloyl)-ATP (mantATP, Jenna Bioscience). Muscle tissue was collected in accordance with the 
U.K. Animals (Scientific Procedures) Act 1986 and associated guidelines. 
Results 
Test of the system 
To test the micro-volume system we compared the transients observed for a standard reaction using 
the stopped-flow system in normal mode with those using the micro-volume unit (MVU). Due to the 
MVU being added between the drive syringes and the observation cell the dead time was 
investigated to see if this was affected. Here a 0.5 µM complex of pyrene labelled actin and myosin 
subfragment 1 (pyr-A.S1) was dissociated by addition of 10 µM to 2 mM MgATP. The reaction was 
observed as a large increase in pyrene fluorescence (F) as the S1.ATP dissociated from the pyr-A. The 
acto.S1 was loaded into the system via the MVU while the ATP was loaded using the standard 
method so that one syringe contained buffer and the other ATP. Figure 2A shows the transients 
using 10 µM and 2 mM MgATP with both the standard and MVU setups. The averaged transients 
shown demonstrate that the  signal-to-noise of the standard and MVU are comparable as expected 
since the optical cell is identical in both cases. Small differences changes in fluorescence baseline are 
attributed to the time taken switch between experimental setups.  As the MgATP concentration was 
increased from 10 µM to 2 mM the kobs also increased, this results in a loss of fluorescence 















plot of the ln(ΔFl) versus the kobs (Figure 2B) was linear and the slope defines the dead time of the 
stopped-flow machine. For the standard setup this was 0.64 ± 0.08 ms and for the MVU this was 
0.56 ± 0.08 ms and therefore very similar and compared with the manufactures estimate of 0.7 ms. 
This is to be expected because the observation cell volume and shot volumes and flow speeds do not 
change between the two methods.  
To investigate the number of usable transients different volumes of 0.5 µM pyr-A.S1 were loaded 
and mixed against 10 µM MgATP with 20 shots measured to observe the washout of the sample. 
Figure 3A illustrates a selection of transients collected using the MVU with a 120 µL loading volume 
and using 20 µl shots (10 µl from each syringe) and a 5 µl observation cell.  Each transient could be 
well described by a single exponential function Ft = Fo·exp(-kobs.t) where kobs is the pseudo first order 
rate constant for ATP binding to pyr-A.S1. From the first shot (not shown) the observed amplitude of 
the transient was large (~40%) and relatively consistent over the first 6 shots (60 µl from each 
syringe) and then decayed rapidly such that by shot 10 the amplitude was only a quarter of the 
starting value.  This decline in amplitude represents the wash out of the sample. Figure 3B plots the 
relative amplitude (observed amplitude/end point to correct for small differences between total 
intensity) against shot number and compares it with that of the same solution using the standard 
stopped-flow set up (filled squares). Three loading volumes (80 µl – open squares, 100 µl – closed 
triangles and 120 µl – open triangles) were investigated to determine the minimum loading volume 
that could be used and still obtain similar traces to that seen with the standard set up. While the 80 
and 100 µl load volumes did give similar traces to that seen with the standard method, the initial 
shots increased in relative fluorescence amplitude to that seen with the standard method before 
washing out as seen with the 120 µl load volume. This was attributed to the load volume not being 
sufficient to completely fill the sample lines from the loading cup to the observation cell, therefore 
there was dilution of the sample in the first few shots with the buffer proceeding it. With the 120 µl 















Note that the best fit kobs values (24.2 ± 0.3 s
-1
) were independent of shot number over the range 1 – 
11 indicating the correct kobs could be estimated even for very low amplitudes.  This is because the 
kobs is independent of protein concentration but linearly dependent upon ATP concentration.  ATP 
was maintained constant as we did not use the loading loop for this reagent. 
The pyrene actin signal is very strong with a large signal change.  The same test was therefore 
repeated with a much weaker tryptophan fluorescence signal (Figure 4).  In the absence of actin, ATP 
binds to S1 with a 12-15 % increase in fluorescence. 10 µM ATP was rapidly mixed with 0.5 µM S1 
and the tryptophan signal recorded.  As before a 120 µL sample was loaded into one loading loop 
and a series of 20 µL shots collected. ATP was loaded using the standard set up so that one syringe 
contained buffer and the other contained ATP. Figure 4A illustrates how the signal was both much 
weaker and with a smaller amplitude compared to pyrene-actin, but the number of useful shots is 
very similar (shots 1-7). The amplitude is reasonably constant for shots 1-7 with a 120 µl loading 
volume then begins to decrease sharply after shot 7 returning to baseline by shot 13 (Figure 4B).  
The weaker, noisy signal gives more variation in the fitted value of kobs (22.8 ± 0.7 s
-1
) but within the 
limits of the noise. As with the pyrene-labelled actin a 120 µl load volume gave the most consistent 
traces over the most number of shots before the sample began to wash out. 
KD measurements 
Having determined an appropriate loading volume of 120 µl that allowed us to obtain consistent 
traces over a limited number of shots, we then investigated whether we could perform a series of 
assays and obtain data similar to the standard setup. A method developed by Kurzawa and Geeves 
[11] for determining the actin affinity of S1 relies on monitoring the relative fluorescence amplitude 
as a varied concentration of S1 is pre-incubated with a fixed (30 nM) concentration of actin and 
rapidly mixed with a fixed (20 µM) concentration of ATP. As the S1 concentration was increased the 
relative fluorescence amplitude also increased as more of the pyrene labels that were initially 















amount of protein with µM amounts of S1 being needed in some cases. This assay then lends itself 
very well to testing the applications of the micro-volume unit. 
Figure 5A shows example traces of 30 nM pyrene labelled actin pre-incubated with varied 
concentrations of S1 then rapidly mixed with 20 µM MgATP in the stopped-flow. The pyrene labelled 
actin.S1 was loaded into the micro-volume unit while the MgATP was loaded via the standard 
method of the drive syringes. The relative fluorescence amplitudes could then be plotted against the 
S1 concentration which was best described by a quadratic equation (Eq 1, Figure 5B). 
∝ =
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Figure 5B shows triplicate repeats of this assay to highlight the reproducibility of the data obtained 
by the micro-volume unit. The average KD value from the three repeats was 45.5 ± 2.6 nM which is in 
good agreement with the findings of Kurzawa and Geeves which was 44 nM [11]. 
pCa measurements 
A second assay that requires a large amount of protein is the calcium sensitivity assay where actin is 
complexed with the thin-filament calcium-regulatory proteins [12] – tropomyosin and troponin. The 
assay is conducted in a series of Ca-EGTA buffers containing increasing concentrations of free 
calcium and therefore requires a different solution filling both syringes of the stopped-flow for each 
new calcium concentration. In this assay a solution of myosin S1 was mixed with a 10 fold excess of 
actin·TmTn at different free calcium concentration (Fig 5 A & B).  At high calcium concentrations all 
the actin sites are available and a single exponential was observed as S1 binds to 1 in 10 of the 
available sites (pseudo first order in [actin]). Here kobs = [actin]k+1 where k+1 is the 2
nd
 order rate 
constant for S1 binding to actin.  As calcium concentration is reduced the TmTn complex blocks 
access to a fraction of the actin sites reducing the effective concentration of available actin.    In this 
case   kobs =  [actin]k+1·KB/(1 + KB) and KB = [Ablocked]/[Aavailable].  A plot of kobs vs calcium concentration 















The same experiment can be repeated but reversing the two protein concentrations; mixing a ten-
fold excess of myosin S1 with actin·TmTn.  This approach uses much less actin·TmTn but conversely 
more myosin S1.  The reaction is also more complex to analyse because as S1 binds to actin·TmTn at 
low calcium concentration it displaces TmTn from actin making more actin sites available thus 
accelerating the binding reaction.  Fig 5 C illustrates how the reaction changed from an exponential 
to sigmoid binding transient as calcium concentration was reduced.  Full analysis of the reaction is 
complex [13] but a simple plot of half-times for the transient (Fig 5D) yielded a similar plot to that of 
Fig 5B.  
Myofibrils  
Myofibrils (muscle cell fragments a few 10’s of µm long containing the intact sarcomeres) are an 
important way of measuring muscle mechanics of an organised system [14–16]. Some biochemical 
kinetic studies have used rapid mixing systems with myofibrils [17,18] combined with either intrinsic 
tryptophan fluorescence or pyrene labelling of actin [18]. A limitation of using the tryptophan 
fluorescence is that high concentrations (3 µM) were needed. Labelling the myofibrils with pyrene 
could be a reasonable alternative but due to indiscriminate binding there is no guarantee that only 
cysteine-374 of actin would be labelled [17,18]. Here we have used mantATP, a fluorescently 
labelled ATP analogue, which increases in fluorescence when bound to myosin [17,19]. Figure 7A 
shows example traces of 200 nM Mouse Gastrocnemius myofibrils rapidly mixed with varied 
mantATP concentrations using the micro-volume unit. These traces using both the standard setup 
and MVU were best described by a double exponential, with the fast phase associated with the 
mantATP binding and the second phase of unknown origin. Previous work using S1 and mantdATP 
showed that two phases were present when only one isomer of mantATP was used [20]. When 
looking at tryptophan fluorescence Stehle et al also witnessed this slow phase and attributed it to 
the ATP hydrolysis step [18]. For our purposes we have focused on the fast phase as this the 















fluorescently tagged, as the concentration of mantATP increases so does the background 
fluorescence signal and therefore at high mantATP concentrations the signal change associated with 
binding is lost in the noise. We were unable to perform a full ATP binding assay because of this, 
however we were able to determine the K1k+2 value over a smaller mantATP concentration (1-5 µM 
mantATP). When the kobs is plotted against the mantATP concentration (figure 7B) there is a linear 
dependence which from the slope gives the K1k+2. Figure 7B shows the averages for the standard 
setup (black squares) and the MVU setup (empty squares) which are in good agreement with each 
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Discussion  
Summary of performance 
We have described here assays that rely on measuring the change in fluorescence, and changes in 
the observed rate constant using the MVU with results comparable with published data using the 
standard stopped-flow setup. Once accustomed to the method of loading samples on the stopped-
flow using the MVU, the process is the same as the standard setup. The same caution should be 
taken as with the standard setup to avoid as best as possible air bubbles from entering the system.  
Mass of protein used in each assay 
Reducing the volume of the samples loaded onto the stopped-flow in combination with the low 
concentrations being used means the mass of protein in each assay is now reduced at least 4 fold 
compared the standard system . Table 1 shows the estimated quantity of protein used in each of the 
assays presented here compared to using the standard setup. The calculations assume the MVU uses 
120 µl samples per data point. As listed in Table 1 the quantities of S1 need for the assays of figure 5 
& 6 are < 50 μg in each case.  Note that actin, tropomyosin and troponin are not usually in limited 















purified from ~ 100 mg of mammalian muscle tissue  or the 100-225 µg from the indirect flight 
muscle of 170-250 Drosophila [21].  
To perform the full set of assays to characterise the kinetics of a myosin such as we have done with 
recombinantly expressed human S1, [22–26] and based on 1 mg/ml of S1 ≈ 8 µM and that 0.12 ml 
was used for the collection of each data point, the total amount of required is 0.3 mg. 
Potential uses  
Stopped-flow is a very powerful tool for teasing apart the fast kinetic steps (millisecond time scale) 
of chemical and biochemical reactions. One limiting factor has always been the amount of sample 
needed to perform measurements. Improved sensitivity of the equipment and more potent 
fluorophores have helped to reduce the concentrations needed in experiment. Using the micro-
volume method presented here improves the economy of sample usage even further and now will 
allow studies not previously possible with a reduction in protein used by at least 1/4 (see above).  
Our interest is in muscle proteins, in particular myosins where large quantities of protein are often 
not available.  Tissue purified protein often contains a mixture of isoforms and so complicates the 
interpretation of data.  Single mammalian muscle fibers normally contain a single isoform [27] and 
purification of myosin from single muscle fibers (typically 0.1 x 10-20 mm) can yield ≈2 µg of myosin 
in 50 µl [28].  
Conventional expression systems using E. coli and Baculovirus are not applicable for recombinant 
myosin expression due to a lack of appropriate chaperones [29–33]. Recombinant human myosin 
motor domains  have been successfully produced using a mouse C2C12 cell system [34] and from 
this characterisation of 7 of the 8 skeletal and cardiac myosin isoforms have been completed along 
with mutations in the myosin that lead to myopathies [22–26,34,35]. A drawback to this method of 















mammalian cells) and obtaining small quantities of motor domain (≈1-2 mg). By using the method 
presented here it will be possible to perform more assays with the limited amount of protein. 
Failing a recombinant expression system the only alternative source of muscle myosin is from muscle 
tissue. Samples of this type bring up moral and ethical issues and as scientists we should abide by 
the 3 R’s (Replace, Reduce, and Refine).  Human muscle biopsies come from two sources needle 
biopsies from volunteers and samples from tissue banks often holding samples from human cardiac 
tissue obtained either from donor hearts not used in transplants or from cardiac septal myectomies.  
Such samples are very small ≈100 mg. Such tissue samples will now prove useful for either protein or 
myofibril studies. An advantage of using biopsy samples over recombinantly expressed proteins is 
that in muscle myopathies myosin can carry a range of post translational modification and 
individuals are usually heterozygous for the mutations. Being able to use biopsy tissue will allow us 
to test how a mixture of wild type and mutant proteins behave. 
Myofibrils 
This modification is a simple and effective method of reducing the volume of sample required to 
perform stopped-flow assays whilst maintaining the accuracy of the standard set up of the machine. 
This could allow researchers with limited samples to be able to use this method in an efficient 
manner saving them both time and money.  
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Figure 1. (A) Diagram of the micro-volume unit attached to the stopped-flow system.   The micro-
volume unit sits between the drive syringes and the mixing chamber of a standard stopped-flow 















to be drawn into the sample tubes between the valves and the mixing chamber using the stopping 
syringe. Switching the valves connects the drives syringes (containing buffer) to the mixing chamber. 
Approximately 7 x 20 μl shots (10 μl from each of lines a & b) can be collected reproducibly – see 
Results. (B) Photo of the rear of the stopped-flow drive unit showing the matching face of the micro-
volume unit.  (C) Photo of the rear of the micro-volume unit.  The filling/drive lines for one of the 
three lines (sample a, b and the waste) is indicated in white.  Only one line is drawn as the circuit is 
complex in 3D.   The mixing/observation assembly affixes to the other face of the unit via an 
























Figure 2: Dead time calibration of the MVU compared to the standard setup using Rabbit pyrene-
labelled actin.S1 (pyr-A.S1) rapidly mixed with MgATP. (A) 0.5 µM pA.S1 was rapidly mixed with 
either 10 µM or 2 mM MgATP using the standard set (black lines) up or the MVU (red lines). As the 
concentration of MgATP increases so does the observed rate constant (kobs). These were best 
described by a single exponential. (B) A plot of the ln(change in fluorescence) versus the kobs results 
in a linear dependence, the slope of which gives the dead time of the machine. For the standard 










































































Figure 3: ATP induced dissociation of pyrA.S1 by ATP. 20 µM ATP was loaded into one drive 
syringe as per the standard stopped-flow method while buffer was loaded into the other 
drive syringe. 120 µL of 1 µM pyrA.S1 was loaded into the loading loop of the MVU before 
20 ‘shots’ were collected. (A) A selection of the 20 transients are displayed to show that the 
protein is present at a high concentration in the first 6-7 shots. The change in fluorescence 
decreasing shows the acto.S1 washing out of the system and buffer is replacing it. (B) The 


































Figure 4: 120 µL 0.5 µM rabbit myosin S1 rapidly mixed with 10 µM ATP. ATP was loaded 
into the drive syringe as per the standard stopped-flow method while buffer was loaded in 
the other drive syringe. 120 µL of 1 µM S1 was loaded into the flow circuit via the MVU 
before 20 ‘shots’ were collected. (A) A selection of transients have been displayed to show 
that the initial 6-7 transients contain protein and have high amplitudes. After this the 
protein concentration rapidly decreases as it is replaced with buffer reducing the 















method (closed squares) versus MVU using a loading volume of 80 µl (open squares), 100 µl 


















Figure 5: Actin affinity of varied rabbit psoas S1 pre-incubated with 30 nM actin rapidly 
mixed with 20 µM MgATP using the MVU. The S1 concentration was varied from 0 to 1 µM. 
(A) Averaged traces from one actin affinity assay. Again each trace was best described by a 
single exponential which are shown with a solid line.  These traces have also been 
normalised to the start point. (B) Quadratic fit of the relative amplitude versus the S1 
concentration. All three repeats have been shown with individual KD values of 41.7 ± 7.7 nM, 
50.5 ± 16.9 nM, and 44.2 ± 13.9 nM. This gave an average KD value of 45.5 ± 2.6 nM which is 

















Figure 6: pCa assays using excess actin or excess S1. (A & B) 0.25 µM Rabbit Psoas S1 was rapidly 
mixed with 10-fold excess pyrene-labelled actin incubated with 2.5 µM skeletal control proteins at 
different calcium concentrations. (A) Averaged traces from a series of pCa concentrations. These 
were best described by a single exponential which are shown with a solid line. These traces have 
been normalised to highlight that the rate constant of S1 binding increases at higher calcium 
concentrations. (B) A Hill coefficient plot of the observed rate constant versus the pCa. This gave a 
pCa50% value of 5.95 which is in agreement with the published value of 6.02 [12]. (C & D) 0.25 µM 
pyrene-labelled actin + 0.25 µM skeletal control proteins were incubated together then rapidly 















from a series of pCa concentrations. The traces have been normalised to highlight that there is a 
change in the half-time as the calcium concentration increases. (D) A Hill coeffient plot of the t1/2 
which is determined as the time at 50% fluorescence. This plot results in a pCa50% of 6.2 which again 




























Figure 7: 200 nM Mouse Gastrocnemius Myofibrils were rapidly mixed with varying concentrations 
of mantATP. (A) Average traces obtained by mixing myofibrils with varied mantATP concentrations 
(1-5 µM) using the MVM. These were best described by a double exponential fit. The traces shown 
are 2 µM (black line), 3 µM (dark grey line), and 4 µM (light grey line) mantATP. These traces have 
been normalised to highlight that there is an increase in kobs as the mantATP concentration 
increases. (B) A linear regression plot of the kobs at mantATP concentrations 1-5 µM. The standard 




 while the micro-volume unit set-up gave a 




. Error bars are standard error of the mean. All concentrations are those 
after mixing. 





















































Actin affinity Standard 138.3 5 - - - 
MVU 33.2 1.2 - - - 
pCa - Excess Actin Standard 115 420 187.4 198.8 - 
MVU 27.6 100.8 45 47.7 - 
pCa - Excess S1 Standard 1150 42 18.7 19.88 - 
MVU 276 10 4.5 4.77 - 
mantATP binding to 
myofibrils 
Standard - - - - 1123 
MVU - - - - 269 
 














• Reduced the volume of sample required in stopped flow systems by a factor of 4 
• Many assays using muscle proteins can be completed with <100 µg of protein 
• This is the quantity of protein available from <100 mg of muscle tissues 
• This will allows assays of human muscle proteins from biopsy tissue 
 
